For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide.

Last updated: April 6, 2024
Sponsor: Qianfoshan Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

Stroke

Blood Clots

Cardiac Ischemia

Treatment

Butylphthalide

Clinical Study ID

NCT05068349
QFS-HX-2021-DBT-001
  • Ages > 18
  • All Genders

Study Summary

This is a prospective, open, single-arm, the real world of clinical trials. The researchers plan to recruit 300 eligible patients. The main purpose of this study is to evaluate the effectiveness and safety of butylphthalide in the treatment of ischemic stroke, and to establish a population pharmacokinetic model of butylphthalide in elderly patients to explore its blood drug concentration. Correlation with its efficacy and adverse reactions.

Eligibility Criteria

Inclusion

Inclusion Criteria:

    1. Female or male aged ≥ 18 years.
    1. Acute ischemic stroke within 48 hours of onset
    1. Examination to exclude intracranial hemorrhage
    1. Provision of informed consent.

Exclusion

Exclusion Criteria:

  • 1.Head CT or MRI suggests the presence of intracranial hemorrhagic disease
  • 2.Patients with cerebral embolism or suspected cerebral embolism with severeatrioventricular block disease, atrial fibrillation, myocardial infarction, heartvalve disease, infective endocarditis, heart rate less than 50 beats per minute
  • 3.Abnormal liver function (transaminase ALT or AST exceeding the upper limit ofnormal), abnormal renal function (creatinine exceeding the upper limit of normal), orsuffering from other serious systemic diseases, etc
  • 4.Allergy to Butylphthalide

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: Butylphthalide
Phase: 4
Study Start date:
May 07, 2022
Estimated Completion Date:
December 31, 2025

Study Description

Ischemic stroke is one of the diseases that seriously threaten human health, with the characteristics of high incidence, high disability and high recurrence rate. Patients will not only suffer from impaired physical function, but also mental symptoms, social function and other obstacles, which seriously affect the quality of life.

Butylphthalide can improve the damage of central nervous system in patients with acute ischemic stroke, and can promote the improvement of patients with neurological deficits. Regarding the treatment of ischemic stroke with butylphthalide, there is still a lack of big data research based on real-world efficacy and safety; there is a lack of data on the pharmacokinetics of elderly patients and their correlation with adverse reactions.

Thus, it is estimated that 300 patients will be enrolled and given intravenous butylphthalide sodium chloride injection 25mg twice a day for 7-14 days, and then oral butylphthalide soft capsule 0.2g three times a day for 76-83 days. The patients will be collected for experiment before and after treatment. Laboratory data, electrocardiogram, NIHSS, mRS, combined medication and adverse events, etc., to evaluate the effectiveness and safety of butylphthalide in the treatment of ischemic stroke. In addition, a population pharmacokinetic model of butylphthalide in elderly patients was established for 50 of them.

Connect with a study center

  • Shandong Provincial Qianfoshan Hospital

    Jinan, Shandong Provincial
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.